Celldex Therapeutics ((CLDX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Celldex Therapeutics is conducting a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis. The study aims to evaluate the effectiveness and safety of barzolvolimab in treating adults with prurigo nodularis, a chronic skin condition characterized by itchy nodules.
The study tests the biological intervention, barzolvolimab, administered subcutaneously. Participants receive either 150 mg or 300 mg doses every four weeks after an initial 450 mg loading dose, or a placebo, to determine the treatment’s efficacy and safety.
This interventional study uses a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary purpose is treatment-focused.
The study began on April 12, 2024, with a primary completion date yet to be determined. The last update was submitted on June 24, 2025, indicating ongoing recruitment and study progress.
The outcome of this study could significantly impact Celldex Therapeutics’ stock performance and investor sentiment, especially if barzolvolimab proves effective. This could position Celldex favorably in the competitive dermatological treatment market.
The study is currently ongoing, with further details available on the ClinicalTrials portal.